Colospan

Company Overview

Snapshot

Founded in December 2010 by Boaz Assaf, Colospan operates with 11–50 employees. The company has raised a total of $17M across 3 funding rounds from 6 investors. In June 2026, Colospan was acquired by Galmed Pharmaceuticals.

Business overview

Colospan is a clinical-stage medical device company focused on developing proprietary technology for colorectal surgery. Its core product, CG-100, is a single-use, temporary intraluminal bypass device designed to prevent anastomotic leaks and divert colonic stomas. The company serves the medical devices and surgical instruments markets within the Health Tech & Life Sciences sector, targeting surgeons and hospitals in Europe and the United States.

Strategic signal

In June 2026, Galmed Pharmaceuticals acquired Colospan, signaling a strategic move to create a GI-focused platform. This acquisition integrates Colospan's FDA Breakthrough Device-Designated technology and active U.S. pivotal IDE trial into Galmed's portfolio, positioning the combined entity to address a significant market in colorectal surgery. The transaction highlights the value of innovative medical devices in preventing surgical complications and expanding market reach.

Company Intelligence Q&A

What was the most significant corporate development for Colospan in June 2026?

In June 2026, Colospan was acquired by Galmed Pharmaceuticals. This transaction was restructured to prioritize the European commercialization of CG-100 and protect shareholder value.

What recent clinical study results were announced for Colospan's technology?

In August 2026, Galmed Pharmaceuticals announced successful first-in-human proof-of-concept clinical study results for Colospan's novel intraoperative tissue assessment technology. The study enrolled 32 colorectal cancer patients at three clinical centers in Israel.

When did Colospan receive FDA approval for its intraluminal bypass device?

In January 2020, Colospan announced FDA approval of an Investigational Device Exemption (IDE) for its intraluminal bypass device, CG-100, offering an alternative approach to diverting stoma.

Which hospital was the first in the U.S. to test Colospan's CG-100 device?

In December 2020, Henry Ford Hospital became the first in the U.S. to test the novel CG-100 intraluminal device in patients undergoing colorectal anastomosis.

What significant funding did Colospan receive in December 2021?

In December 2021, Colospan received €8.2 million from the European Innovation Council for its novel colorectal surgery device.